More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Growth in Eliquis drug also led to an upside in the top line. Consequently, the company raised its annual earnings guidance. Following this, the stock also rallied. BMY is banking on newer drugs ...
Get detailed information on Apixaban, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
The company's position is bolstered by strong performers like Eliquis, but it also faces challenges from both branded competitors and the looming threat of generic competition. The impact of the ...
NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...
This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
Hosted on MSN5d
What's Behind the Insider Buying on This High-Yield Stock?The biopharma industry is on an upward trajectory, driven by groundbreaking advances in treatment options and a rising demand ...
and Pfizer's Eliquis (apixaban), an oral anticoagulant, will be the second best-selling drug out of the top ten, with annual sales of $18.7 billion by 2025. “Keytruda is expected to overtake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback